Cart
sales@molnova.com
Solanezumab
CAS No. 955085-14-0
Solanezumab( —— )
Catalog No. M36734 CAS No. 955085-14-0
Solanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 375 | Get Quote |
|
| 5MG | 613 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1408 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2511 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSolanezumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSolanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.
-
DescriptionSolanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetBeta Amyloid
-
RecptorBeta Amyloid
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number955085-14-0
-
Formula Weight144.1 (kDa)
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Honig LS, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018 Jan 25;378(4):321-330.?
molnova catalog
related products
-
β-Amyloid 29-40
β-Amyloid (29-40) is a fragment of Amyloid-β peptide.Alzheimer's beta amyloid peptide (29-40/42) C-terminal fragments have physical and chemical properties related to those of fusion peptides of viral proteins. The fusion of liposomes can be induced by these peptides in vitro.
-
PPI-1019
PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).
-
DSS30
DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).
